Linezolid Panpharma

Linezolid, the active ingredient in Linezolid Panpharma, is an oxazolidinone presented as an injectable solution for intravenous use. It treats infections caused by susceptible Gram‑positive bacteria, including MRSA and VRE, in hospitalized patients.

GNH USA supplies Linezolid Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is indicated for serious infections caused by Gram‑positive bacteria, acting on resistant and susceptible strains. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides effective bacteriostatic activity against resistant Staphylococcus aureus. - Vancomycin‑resistant Enterococcus (VRE) infections: treats infections caused by vancomycin‑resistant Enterococcus species. - Community‑acquired and hospital‑acquired pneumonia: covers typical Gram‑positive pathogens in lower respiratory tract infections. - Skin and soft‑tissue infections: resolves complicated SSTIs caused by susceptible organisms. - Complicated infections caused by susceptible Gram‑positive bacteria: offers broad coverage for serious systemic infections.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: mild to moderate intensity. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Anemia: reduced red blood cell levels. - Peripheral neuropathy: nerve damage causing tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Optic neuropathy: potential vision changes.

Use of Linezolid requires careful monitoring and specific safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver enzymes regularly. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Myelosuppression: perform routine blood count monitoring. - Pregnancy Category B: prescribe only when benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): can precipitate serotonin toxicity. - Rifampin: induces metabolism, reducing linezolid exposure. - Warfarin: may increase anticoagulant effect and bleeding risk. - Phenylpropanolamine: potentiates hypertensive reactions.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased bleeding tendency. - Diuretics: additive hypotensive effect. - Carbamazepine: may lower linezolid concentrations. - Oral contraceptives: possible reduction in efficacy. - Other bacteriostatic antibiotics (e.g., chloramphenicol): potential antagonism.